Introduction
Peyronie's disease is a connective tissue disorder of the penis characterized by ®brous inelastic scar formation involving the tunica albuginea of the corpora cavernosa and adjacent erectile tissue. 1, 2 It is most commonly seen during the ®fth decade. 3, 4 Clinical manifestations include penile deformity, palpable plaque on the shaft of penis and pain on erection. 3 Sexual dysfunction, being a part of presenting symptoms, is reported to be 4 ± 80% among different series. 5 ± 7 Patients with Peyronie's disease do not have a common starting point and a well-de®ned end point is conceptually dif®cult but two discernible phases are usually noted during the progression of the disease. 8 The acute in¯ammatory phase usually lasts about 12 ± 18 months and the clinical hallmarks are unstable penile deformity and pain on erection. 9 The deformity, which is a dorsal penile curvature in most cases, may sometimes appear in an hyperacute fashion described as occurring overnight by the patient or may develop insidiously over weeks or months. The chronic or stable phase begins when the acute phase subsides and it is characterized by stable penile deformity and minimal pain on erection. 3, 9 During the acute phase, the lesions on the tunica albuginea show in¯ammatory in®ltrate while those of long duration exhibit ®brosis, calci®cation and sometimes ossi®cation. 10 ± 14 Although complete resolution has been reported to occur without treatment in up to 13% cases, it often takes several years. 8 Therefore, the treatment of Peyronie's disease can be initiated by medical therapy modalities during the acute phase. 9, 15 Surgical treatment should be delayed until the acute in¯ammatory phase has resolved and must be considered in patients with severe but stable deformity that impairs sexual function. 16, 17 Despite the extensive clinical experience, a standard and worldwide-accepted consensus for the medical treatment of Peyronie's disease remains lacking. Various agents have been reported to improve the deformity to some extent but none of these agents have been successful enough to overcome the problem. 18 Peyronie's disease is a condition with diminished collagen turnover and extensive ®brosis. 9 ± 14. Thus, agents affecting the collagen synthesis and degradation may improve the progression of the disease. In a preliminary report, treatment with oral colchicine, which induces collagenase activity and decreases collagen synthesis, has been reported to have satisfactory results. 19 Furthermore, colchicine treatment has been shown to suppress the Peyronie's-like condition in the rat model. 15 In this report, we describe our experience in the treatment of Peyronie's disease with oral colchicine and correlate the characteristics of our patients with long-term results in order to identify predictive parameters of successful outcome.
Materials and methods
During a 6-year period between 1993 and 1998, 231 men with Peyronie's disease were seen at our outpatient department and 42.3% (n 98) were indicated for medical treatment since they presented during their acute phase (duration`12 months) of the disease. Of these 98 patients, 60 were eligible for participation in our non-randomized prospective study, which was designed to evaluate the effect of oral colchicine on the progression of Peyronie's disease. None of the patients enrolled into this study had undergone previous therapy for Peyronie's disease.
The ®rst part of patient evaluation was directed toward a detailed medical and sexual history. Presence of risk factors for vascular disease such as diabetes mellitus (IDDM and NIDDM), hypertension and serum lipid abnormalities were recorded. 20 Erectile status of the patients was questioned and patients with inability to achieve or maintain erection of suf®cient rigidity and duration to permit satisfactory sexual intercourse were considered to have erectile dysfunction (ED) by history. 21 Physical examination focused on abnormalities of the external genitalia.
All patients were given an intracavernous injection of 60 mg papaverine combined with manual genital stimulation (CIS test) to assess the degree of tumescence, location and degree of the curvature. 22 Criteria for positive erectile response to CIS test were determined by the occurrence of erection (buckling pressure b500 g) within 10 min and the duration of this state for at least 10 min. 17, 22 A vacuum erection device (VD) was used to achieve full erection in patients with negative response to CIS test. The degree of the curvature was measured with a protractor during maximum erection in response to CIS test andaor VD in all cases and the deformities were also documented by photographs or drawing. In an effort to evaluate the outcome the treatment based on varying degree of curvature, a modi®ed Kelami's classi®cation was used as follows: grade I was a curvature of 30 or less, grade II was a curvature between 30 and 60 and grade III was a curvature greater than 60
. 23 Colchicine was administrated orally with initial doses ranging from 0.5 to 1.0 mg daily, during the ®rst week. 19 The doses were increased gradually, according to the tolerance of each patient, until the maximum dose of 2.0 mg daily (prescribed as 1.0 mg twice daily) was attained. Three to six months of treatment was recommended. Patients were informed about the possible side effects. Complete blood count was obtained prior to therapy and every two months during the treatment.
The success of the treatment was based on subjective and objective criteria. Subjective criteria included patients' own statements during subsequent follow-up visits about painful erections and erectile status by history. The change of penile deformity, assessed by CIS test every three months during follow-up, was taken as the objective criteria. Response to the treatment was classi®ed as`improvement',`no change' and`deterioration' of the criteria, either objective or subjective.
Statistical analysis was performed with chisquare test to compare the impact on outcome of various parameters, such as presence of risk factors for vascular disease, presence of ED by history, response to CIS test, duration of the disease and the degree of deformity.
Results
Patients' ages ranged from 23 to 71 y with a mean age of 51.3 AE 9.8 y. The mean duration of the disease, namely the interval between the onset of the disease and the initiation of colchicine treatment, was 5.7 AE 4.3 (range: 1 ± 11) months. Dorsal penile curvature was the most common (41.7%, n 25) deformity. Lateral curvature of the penis (left in 26.6% and right in 13.3%) was observed in 24 (40%) cases and nine (15%) had a ventral curvature. The remaining two cases (3.3%) had hourglass and swanneck deformities, respectively.
All patients (n 60), except one (1.7%) who had to terminate the treatment due to severe gastrointestinal side effect (ie severe diarrhea), completed the treatment that consisted of 2 ± 6 months. Neither any other severe gastrointestinal side effect indicating termination of the treatment nor any hematological side effect was observed during the treatment. The mean follow-up was 10.7 AE 4.7 (range: 7 ± 18) months.
Objective measurements during follow-up demonstrated that the penile curvature improved in 30% of the cases, remained unchanged in 48.3% and increased in 21.7% (Table 1) . Pain on erection was a presenting symptom in 20 (33.3%) cases and was noted to resolve in 19 (95%) of them (Table 1) . Of those cases with pain disappearing, the deformity was observed to improve in 10 and deteriorate in nine.
The erectile status by history remained unchanged in all cases during follow-up.
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There was a statistically signi®cant difference in response to treatment within patients based on their clinical characteristics. Best results were obtained in patients with no risk factor for vascular disease, presenting during the initial 6 months of the disease, a degree of penile curvature less than 30 , no erectile dysfunction by history and positive response to CIS test ( Table 2 ). The type of the deformity did not seem to affect the response to the treatment (data not shown).
At least 1 risk factor could be demonstrated in 21 (35%) cases ( Table 2 ). Improvement of the penile deformity was noted in 35.9% of the patients with no risk factor versus 19% of those with at least one risk factor; and this difference approached statistically signi®cance (P`0.07). The treatment seemed to stabilize the disease (ie improve or remain unchanged) in 82.1% cases without any risk factor.
All patients enrolled in the study were in their acute phase of disease but improvement of the deformity was noted in a higher percentage (36.4%) of cases presenting during the initial 6 months of the disease ( Table 2) .
The response to the treatment signi®cantly differed in terms of degree of deformity based on modi®ed Kelami's classi®cation ( Table 2) . None of the patients with grade I (`30 ) deformity had deterioration of the curvature and 42.1% had improvement, and the results obtained in this group were signi®cantly better than those obtained in other groups (P`0.01). In patients with grade II (30 ± 60 ) deformity, improvement and deterioration of the curvature was noted in 26.7% and 33.3%, respectively. The treatment resulted in improvement in 18.2% and deterioration in 27.3% cases with grade III (b60 ) deformity (Table 2) . By history, ED was present in 29 cases but they were not given a speci®c medication for this (Table  2 ). Positive and negative responses to CIS test were obtained in 15 and 14 of them, respectively. The response to treatment was signi®cantly better in patients with no ED andaor positive response to CIS test ( Table 2 ). Improvement of the penile curvature was observed in 32.3% and 27.6% cases with or without ED, respectively (Pb0.05). However, deterioration of the curvature was noted in 37.9% and 6.5% cases with or without ED, respectively and this difference was statistically signi®cant (P`0.01; Table 2 ).
Patients with a positive response to CIS test also had a better response to the treatment ( Table 2) . Improvement of the penile curvature was noted in 36.4% cases with a positive response to CIS test and in 12.5% cases with a negative response to CIS test (P`0.05). Similarly, deterioration was observed only in 6.8% cases with a positive response to CIS test while 62.5% cases with a negative response to CIS test experienced deterioration (P`0.001).
Cessation of the treatment did not result in recurrence of deformity or pain.
Discussion
Although a prolonged period of time has elapsed since its original description by Fallopius in 1561, there is still no clear understanding of the etiology of Peyronie's disease. 18 The most widely accepted theory is that, Peyronie's disease is caused by an abnormal ®brotic reaction of tunica albuginea to 12.5% (n 2) 25% (n 4) 62.5% (n 10)
*P`0.05 (chi-share test). ** P`0.01. ***P`0.001. 
repetitive microtrauma to erect or¯accid penis with an inherited predisposition to an exaggerated ®bro-tic response. 8, 24, 25 The natural history of Peyronie's disease is also obscure. 8 The only large, long-term study of the natural history of Peyronie's disease underlines that only 13% of patients experienced gradual resolution of the curvature, 47% remained with little or no change and 40% showed progression. 8 This study clearly demonstrated that the chance of spontaneous resolution is low and usually takes several years. A standard non-surgical treatment modality for Peyronie's disease has yet to be identi®ed. 23 Oral, topical and intralesional treatments have been manifold and usually based on a fairly nebulous rationale. 18 Taking the histopathologic changes and clinical phases of Peyronie's disease in consideration, medical treatment is warranted during the acute phase of the disease. 15 Surgical treatment should be considered for cases during their chronic phase of the disease when the deformity is stable since no medical treatment modality has shown to act against the histopathologic ®ndings of this phase such as extensive ®brosis, calci®cation and ossi®cation. 9, 17 Topical applications of iodine and mercury, intravenous administration of prostaglandin, oral use of disodiumposphate have been tried for the treatment of Peyronie's disease in the beginning of the twentieth century. 18 Attempts to dissolve the plaque by intralesional injection of agents such as mercury, iodine and steroids have taken their place in the history of medical treatment of Peyronie's disease. 18 In a recent report by Levine, objective improvement of the curvature has been demonstrated in 54% cases after intralesional verapamil injections. 23 He proposed that verapamil, as a calcium channel blocker, inhibits exocytosis of extracellular matrix molecules such as collagen (especially type III) and thus decreases ®brosis. He also concluded that poor candidates for medical treatment were the cases with extensive penile deformity (b900) and plaque calci®cation, insisting on rapid and reliable results and those with nonresponsive erectile dysfunction. 23 Supporting these data, Rehman et al reported decrease in plaque volume in 57% of verapamil-treated men. 26 Gelbard et al were able to show an improvement in the curvature in 65% cases with Peyronie's disease after intralesional collagenase injections. 27 Furthermore they reported that best results (100% improvement) were achieved in cases with a curvature`30 and plaque size`2 cm. 27 In an other study by Wegner et al, the curvature improved only in 3.3% while remaining stable in 86.7% after local injections of INF-a2b, which is proposed to alter metabolic activities of myo®broblasts. 28 However, they also underlined the controversies about local INF-a2b therapy since the disease is not limited to the initial plaque site. 28 The search for a`tablet' cure, has put pressure on the investigators and by the mid-twentieth century, oral vitamin E, estrogens and procarbazine joined the treatment armoury. 18 However, these agents deemed to be of limited ef®ciency with severe side-effects, except vitamin E, and the lack of control data was highlighted. Many authors still recommend the use of vitamin E because of its low toxicity pro®le and cost although they do not expect any signi®cant change. 18 Potaba was introduced into the treatment regimen for Peyronie's disease in 1959 by Zarafonetis and Horrax. 18, 29 In a recent report by Carson, treatment with Potaba resulted in improvement in penile angulation in 58% and complete resolution of angulation 25.8%, but had several disadvantages such as its high cost and severe gastrointestinal side effects. 30 Tamoxifen has also been reported to improve the deformity in more than 30% cases but facial¯ushing, reduced libido and ejaculate volume are some of its side effects. 31 Our results resemble the ratio of other series further clarifying actual indications and determining the predictive parameters of successful outcome. Indications of medical treatment, which has not been clearly de®ned in previously published series, is restricted for those presenting during the acute phase of the disease (ie duration of disease`12 months). In a recent study on Peyronie's-like condition in rats, early medical treatment resulted in a better response. 15 The mean duration of Peyronie's disease in our series was 5.7 AE 4.3 months with a range of 1 to 11 months, indicating the acute phase. Another major difference between the previously published series is that we did not consider plaque volume and calci®cation as a parameter to evaluate the outcome since it has been shown that tunica albuginea is affected as a whole in Peyronie's disease. 14, 17, 28, 32 This also encouraged us to treat our Peyronie's patients with systemic oral colchicine. Furthermore, tissue planes between Buck's fascia and tunica may be obscured after intralesional injections resulting in an increased risk of neuro-vascular bundle injury during surgery when indicated. However, this unfortunate side effect has only been observed to occur following intralesional injection of steroids, while verapamil, with its high success rate, does not seem to produce this effect. 19, 22 Currently, management of Peyronie's disease consists of attempts to control its symptoms during the acute phase and treat the resulting disabling penile deformity with surgery during the chronic phase. Thus we believe that any treatment modality, with a proven or theoretical side effect to the anatomy of penis, may make surgery more dif®cult in the future. In our series, 43.3% of cases were candidates for surgery in their chronic phase (data not shown) and we did not encounter any dif®culty during their surgery.
Treatment of
Fibrosis, which is a pathological process characterized by the replacement of normal tissue by mesenchymal cells and extracellular matrix produced by these cells, is a prominent factor in Peyronie's disease. 9 Several factors have been proposed to induce ®brosis and play role in the pathogenesis of Peyronie's disease. Recently, increased expression of TGF-b protein has been shown in tissues from tunica albuginea of Peyronie's disease patients. 9 TGF-b, well known as a cytokine vital to tissue repair, stimulates synthesis of extracellular matrix components including ®bronectin, tenascin, proteoglycans and collagen, while simultaneously blocking matrix degradation. 9, 33, 34 However, its excessive action, which is referred as thè dark side' of tissue repair, may be responsible for tissue damage caused by scarring. 34 An animal model, focusing on the role of TGF-b in the pathogenesis of Peyronie's disease, has been recently introduced by El-Sakka et al. 33 In this model, the same authors were able to show that colchicine suppressed the Peyronie's-like condition by downregulating TGF-b protein expression and underlined the notion that medical treatment of Peyronie's disease with oral colchicine should be started as early as possible. 15 Furthermore, they postulated that microcirculation to the Peyronie's-like area is normal or increased during in¯ammatory phase and thus underlined that an adequate concentration of colchicine would perfuse to that area. 15 On the other hand, this issue has still to be proved by further studies since it is well known that tunica albuginea is a relatively hypocellular and hypovascular tissue.
Colchicine is an inhibitor of collagen synthesis and secretion, promotes collagenolytic activity and suppresses the release of several growth factors. 35 It binds to intracellular microtubuler proteins such as tubulin and mitotic spindle. 19 By binding to the mitotic spindle, colchicine interrupts cellular mitosis and thus inhibits collagen synthesis by ®broblasts. 36 It interferes with the transcellular movement of collagen, reduces the activity of hepatic collagen processing enzymes and stimulates the production of collagenase. 37 It also binds to tubulin, causing it to depolymerize and inhibits the motility and adhesion of leukocytes. 9 Additionally, it inhibits the release of some growth and chemotactic factors. Colchicine has also been shown to interfere with the secretion of several in¯ammatory cytokines (IL-6, IL-8, TNF-a, selectins) and also down-regulates TGF-b protein expression. 15, 35, 38 In the area of in¯ammation, the phagocytic activity is dependent on an intact microtubule structure, which is disturbed by colchicine. 15 Another antiin¯ammatory effect of colchicine is to block the lipoxygenase pathway of arachidonic acid, preventing formation of leukotriens. All these putative anti®brotic and anti-in¯ammatory properties support the notion that colchicine can be useful as a therapeutic agent in ®brotic disorders such as Peyronie's disease. In a preliminary report by Akkus Y et al, oral administration of colchicine resulted in improvement of penile curvature in 37% cases with considerably limited side effects. 19 Furthermore, pain on erection disappeared in 78%. However, the deterioration of the curvature was not mentioned in their study. In our series, improvement of the curvature was observed in 30% while 21.7% experienced deterioration of the curvature after oral administration of colchicine for 2 ± 6 months. There was no change in the curvature in 48.3% cases but pain on erection disappeared in 95%. Although these results are attributed to the anti®brotic effect of colchicine, the natural history of Peyronie's disease is also believed to result in resolution in some (13%) cases. 8 Pain associated with erection is usually an early symptom of the disease and often diminishes or disappears within 12 months after the onset of the disease. But we believe that colchicine shortens this period by inhibiting the in¯ammation. Double blind, prospective clinical studies, which seem unethical, are needed to differentiate the effect of colchicine on the progression of the disease from its natural outcome.
Colchicine has been reported to cause gastrointestinal side effects, such as diarrhea, nausea, vomiting, abdominal pain, and bone marrow suppression in up to 50% cases. 39 Interestingly, side effects as indicators to terminate the treatment were observed only in one patient (1.7%) presenting with severe diarrhea following the treatment. This low prevalence of severe side effects can be attributed to racial differences, withstanding systemic diseases, our policy in adjusting the dosage and close followup. Supporting our thesis, colchicine has been reported to be a relatively safe and effective medication when used in appropriate dosage in patients with normal kidney and liver functions. 40 There was a statistically signi®cant difference in response to treatment within patients in our series based on the presence of risk factors for vascular disease, ED by history, response to CIS test, duration of disease and being within the three modi®ed Kelami's classi®cation groups (Table 2) . Best results were obtained in patients with no risk factor, no ED, positive response to CIS test, presenting during the initial six months of the disease and a degree of penile curvature less than 30 . The major indication of medical treatment in cases presenting with a degree of curvature less than 30 degrees, was pain on erection. Since no one can guarantee that these patients will not have a progressive disease, medical treatment was initiated in these cases in order to stabilize the possible progression.
In order to assess the penile deformity objectively and more accurately, CIS test was performed and VD was used to create a fuller erection in cases with negative response to intracavernous injection. However, the mechanism of erection obtained by VD is not same as that obtained by intracavernous Treatment of Peyronie's disease with oral colchicine A Kadi og AElu et al injection and one must keep in mind that the use of VD may mask the actual degree of the curvature. Erectile status of the patients, namely potency by history and response to CIS test, did signi®cantly effect the outcome.`Deterioration' of the curvature was observed in 37.9% cases with ED by history and in 62.5% cases with a negative response to CIS test; and these ratios were signi®cantly higher (P`0.01) than those obtained in potent or CIS ( ) cases ( Table 2) . A signi®cant higher percentage of CIS ( ) group had`improvement' (P`0.05) while there was no statistically signi®cant difference in term of improvement' within potent and impotent groups ( Table 2 ). Therefore we conclude that patients with ED by history andaor negative response to CIS test have a higher risk of`deterioration' in spite of treatment although the chance of`improvement' is not signi®cantly affected by erectile status. This may be partly explained by oxygenation of the penis and the natural history of Peyronie's disease. It is obvious that Peyronie's patients with ED and negative response to intracorporeal vasoactive agents have a poor penile arterial blood¯ow and thus oxygenation. 17, 41 The role of hypoxemia in ®brosis is also well documented in animal models as well as in clinical reports. 42 At low oxygen tension in the corpora cavernosa, TGF-b synthesis and secretion increases and this induces collagen synthesis and thus ®brosis. 42 Therefore it is inevitable for cases with ED to have a higher risk of extensive ®brosis and poor outcome. Furthermore poor arterial blood¯ow to penis will also decrease the amount of oral drugs available at their site of primary action and intralesional treatment modalities may be the choice of treatment in these cases. 15 Self injection of vasoactive agents may be considered in patients with negative response to CIS test since this will increase oxygenation of penis and may not only decrease the risk of deterioration but also improve the response to oral treatment. 41, 43 
Conclusions
Although intralesional treatment modalities result in a higher success rate, oral colchicine, with its low cost and minimal side effects, may also be considered during the acute phase of Peyronie's disease. In our series with oral colchicine treatment, penile deformity improved in 30% and remained unchanged in 48.7% after a mean follow-up of 10.7 months. The systemic anti-®brotic and anti-in¯am-matory activities of colchicine exerted their effects signi®cantly in those during their early acute phase of disease, with no risk factor for vascular disease and minimal penile deformity. Interestingly, cases with adequate erectile capacity (that is no ED by history and positive response to CIS test) had signi®cantly better response and this was attributed to suf®cient blood¯ow and oxygenation of erectile tissue.
